While I agree with all what you said in your post, I do think confidence should be better injected through
Reading, studying and analyzing what we have learned about the current DCVax-L phase 3 trial for GBM patients, ie, the blinded, blended data published on
and subsequent uptrending updates by Drs LL, Bosch;
the history, status and outcomes of the current standard of care, which indicates there has been almost no change in extending patients' survival both in terms of median or long term survival;
All previous phase 3 trials for GBM, and their respective results, the reasons why they all failed; and
Though despised by the majority of oncologists taking care of their GBM patients for its unclear MOA, difficult to use and added burden for already great hardship of their patients, the FDA approved Optune device has panned out quite well, illustrating the huge unmet demand. And if NWBIO updated its long-term survival data, Novocure would mysteriously come out with some cherry-picking if not outright faked data trying to have a match. All in all, if DCVax-L is approved its market cap shall double, triple the Novocure's which is currently at $19 billion.
It's pretty much certain DCVax-L trial will be significant in meeting its primary endpoint.
WE are siting at a price range of $1.5 ~ $1.7 for quite a time for a market cap of about $1.3 billion.
Some long term holders are trimming fat becoming lighter if not completely out of the game, new comers are mostly bashing (of course they want to initiate a position at a price as low as possible), and from time to time a tiny fraction of warrants gets dumped onto market. We are at a point now even nobody bothers to report their communications with DI or Les. The darkness seems to be upon us. How this situation can last.
I added about 100,000 shares in the last two weeks bringing my average up a bit
News 
Market Data 
Discover 
AI
